UHRF1 Induces Metastasis in Thyroid Cancer

Bo-Hua Kuang,Guo-He Lin,Quentin Liu,Bi-Cheng Wang
DOI: https://doi.org/10.1155/2022/7716427
IF: 4.501
2022-08-14
Journal of Oncology
Abstract:Background. Ubiquitin-like with PHD and ring-finger domain 1 (UHRF1) has been defined as an oncogene in tumor cells. However, the role of UHRF1 in mediating metastasis in thyroid cancer remains unexplored. In this study, we aimed to investigate the metastatic function and the potential mechanisms of UHRF1 in thyroid cancer. Methods. Transwell assays were used to detect the metastatic capability of thyroid cancer. Dual-luciferase reporter assays were applied to examine the activation of transcription factors. Coimmunoprecipitation assays and immunofluorescence staining assays were used to elucidate the potential mechanisms of UHRF1 in promoting the metastasis of thyroid cancer. Results. In this study, we found that overexpression of UHRF1 promoted the metastasis of papillary thyroid cancer cells, and suppression of UHRF1 decreased the metastasis of anaplastic thyroid cancer cells. Regarding the signaling pathway in regulating metastasis, UHRF1 directly combined and activated the transcription factor c-Jun/AP-1 in the nucleus, subsequently increasing the transcription of IL-6 and MIF. Conclusion. Our results suggest that UHRF1 could induce the metastasis of thyroid cancer, and the potential signaling pathway might be that UHRF1 activates c-Jun/AP-1 to increase the expression of IL-6 and MIF. These findings provide a novel mechanism of UHRF1 and illustrate that UHRF1/AP-1 complex could be a potential therapeutic target for patients with thyroid cancer.
oncology
What problem does this paper attempt to address?
The paper primarily explores the role and potential mechanisms of Ubiquitin-like with PHD and RING finger domains 1 (UHRF1) in thyroid cancer metastasis. The study found that UHRF1 can promote the metastasis of thyroid cancer cells and revealed that this process may be achieved by activating the transcription factor c-Jun/AP-1, thereby increasing the expression of pro-inflammatory factors IL-6 and MIF. Specifically, the main contributions of the paper include: 1. Discovering that overexpression of UHRF1 can promote the invasive ability of papillary thyroid cancer cells, while inhibiting UHRF1 can reduce the invasiveness of undifferentiated thyroid cancer cells. 2. The study shows that UHRF1 can directly bind and activate the nuclear transcription factor c-Jun/AP-1, thereby increasing the transcription levels of IL-6 and MIF. 3. A series of experiments validated the direct interaction between UHRF1 and c-Jun/AP-1, and demonstrated that this complex can enhance the expression of inflammation-related cytokines such as IL-6 and MIF. 4. Discussing the potential of the UHRF1-c-Jun/AP-1 complex as a therapeutic target for thyroid cancer. In summary, this study reveals a new role of UHRF1 in thyroid cancer metastasis and proposes a potential therapeutic strategy.